© 2021 MJH Life Sciences and Consultant Live. All rights reserved.
May 07, 2021
Data from the KITE study shows that ≥50% of brolucizumab patients maintained a 12-week interval schedule through 52 weeks.
Patients who utilized virtual and in-person visits had comparable numbers of follow-ups, referrals, and outpatient surgeries.
May 06, 2021
The implant was linked to visual acuity improvements at final follow-up visit.
Animal models suggest the investigative treatment is safe and tolerable in treating retinal vascular diseases.